Filing Details

Accession Number:
0001209191-11-051862
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-10-17 18:32:26
Reporting Period:
2011-10-14
Filing Date:
2011-10-17
Accepted Time:
2011-10-17 18:32:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1012140 Onyx Pharmaceuticals Inc ONXX Biological Products, (No Disgnostic Substances) (2836) 943154463
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1365619 Laura Brege C/O Onyx Pharmaceuticals, Inc.
249 East Grand Ave.
South San Francisco CA 94080
Evp, Corporate Affairs No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-10-14 5,904 $15.44 45,574 No 4 M Direct
Common Stock Acquisiton 2011-10-14 4,096 $24.84 49,670 No 4 M Direct
Common Stock Disposition 2011-10-14 10,000 $36.01 39,670 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2011-10-14 5,904 $0.00 5,904 $15.44
Common Stock Stock Option (Right to Buy) Disposition 2011-10-14 4,096 $0.00 4,096 $24.84
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
36,596 2016-06-12 No 4 M Direct
65,904 2017-03-30 No 4 M Direct
Footnotes
  1. Includes 243 shares purchased through the issuer's ESPP during the year.
  2. Shares sold pursuant to a 10b5-1 plan.
  3. Twenty-Five percent of the shares subject to the option become exercisable 1 year from the date of grant and the remainder become exercisable at a rate of 1/48th per month thereafter.
  4. 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.